Corfluvec / Smorodintsev Research Institute of Influenza - LARVOL DELTA

Novel Intranasal Influenza-Vectored Vaccine Corfluvec Provides Protection Against Influenza and COVID-19, Mitigating SARS-CoV-2-Induced Lung Vascular Damage. (PubMed, Vaccines (Basel)) - " Corfluvec is a promising bivalent vaccine candidate that provides dual protection against influenza and COVID-19. Its ability to limit viral shedding from the upper respiratory tract and to mitigate SARS-CoV-2-induced pulmonary pathology, contributing to the preservation of lung vascular integrity, underscores the utility of mucosal immunization with Corfluvec as a valuable intranasal complement to current systemic vaccination strategies."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Vasculitis • ACACA • CD31 • IFNG • PECAM1

Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1/2 | N=200 | Completed | Sponsor: Tatyana Zubkova | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1/2 | N=200 | Active, not recruiting | Sponsor: Tatyana Zubkova

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease